Swiss National Bank’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-103,800
| Closed | -$1.57M | – | 2775 |
|
|
2022
Q3 | $1.57M | Buy |
103,800
+1,200
| +1% | +$13.9K | ﹤0.01% | 2039 |
|
|
2022
Q2 | $770K | Sell |
102,600
-3,700
| -3% | -$26.1K | ﹤0.01% | 2491 |
|
|
2022
Q1 | $967K | Buy |
106,300
+8,300
| +8% | +$64K | ﹤0.01% | 2421 |
|
|
2021
Q4 | $688K | Hold |
98,000
| – | – | ﹤0.01% | 2590 |
|
|
2021
Q3 | $1.12M | Hold |
98,000
| – | – | ﹤0.01% | 2380 |
|
|
2021
Q2 | $1.57M | Buy |
98,000
+7,000
| +8% | +$120K | ﹤0.01% | 2255 |
|
|
2021
Q1 | $1.63M | Buy |
91,000
+1,600
| +2% | +$27.6K | ﹤0.01% | 2128 |
|
|
2020
Q4 | $1.21M | Buy |
89,400
+1,300
| +1% | +$15.7K | ﹤0.01% | 2201 |
|
|
2020
Q3 | $1.04M | Hold |
88,100
| – | – | ﹤0.01% | 2070 |
|
|
2020
Q2 | $1.3M | Buy |
88,100
+2,900
| +3% | +$42.9K | ﹤0.01% | 1947 |
|
|
2020
Q1 | $1.15M | Buy |
85,200
+1,700
| +2% | +$32.3K | ﹤0.01% | 1743 |
|
|
2019
Q4 | $2.02M | Buy |
83,500
+1,600
| +2% | +$33.1K | ﹤0.01% | 1727 |
|
|
2019
Q3 | $1.57M | Buy |
81,900
+1,500
| +2% | +$34.4K | ﹤0.01% | 1792 |
|
|
2019
Q2 | $2.38M | Buy |
80,400
+5,900
| +8% | +$227K | ﹤0.01% | 1589 |
|
|
2019
Q1 | $3.54M | Buy |
74,500
+2,500
| +3% | +$110K | ﹤0.01% | 1305 |
|
|
2018
Q4 | $2.6M | Buy |
72,000
+10,000
| +16% | +$469K | ﹤0.01% | 1395 |
|
|
2018
Q3 | $3.82M | Buy |
62,000
+2,900
| +5% | +$186K | ﹤0.01% | 1292 |
|
|
2018
Q2 | $3.99M | Buy |
59,100
+5,200
| +10% | +$291K | ﹤0.01% | 1244 |
|
|
2018
Q1 | $2.92M | Buy |
53,900
+1,300
| +2% | +$72.7K | ﹤0.01% | 1391 |
|
|
2017
Q4 | $3.14M | Buy |
52,600
+2,300
| +5% | +$139K | ﹤0.01% | 1355 |
|
|
2017
Q3 | $2.44M | Buy |
50,300
+3,500
| +7% | +$191K | ﹤0.01% | 1479 |
|
|
2017
Q2 | $2.46M | Hold |
46,800
| – | – | ﹤0.01% | 1458 |
|
|
2017
Q1 | $2.12M | Buy |
46,800
+3,600
| +8% | +$161K | ﹤0.01% | 1520 |
|
|
2016
Q4 | $1.64M | Hold |
43,200
| – | – | ﹤0.01% | 1705 |
|
|
2016
Q3 | $1.63M | Buy |
43,200
+5,000
| +13% | +$110K | ﹤0.01% | 1644 |
|
|
2016
Q2 | $672K | Buy |
38,200
+5,100
| +15% | +$82.6K | ﹤0.01% | 2193 |
|
|
2016
Q1 | $388K | Buy |
33,100
+6,400
| +24% | +$101K | ﹤0.01% | 2416 |
|
|
2015
Q4 | $650K | Hold |
26,700
| – | – | ﹤0.01% | 2112 |
|
|
2015
Q3 | $474K | Buy |
26,700
+4,300
| +19% | +$77.9K | ﹤0.01% | 2206 |
|
|
2015
Q2 | $395K | Buy |
22,400
+4,800
| +27% | +$88K | ﹤0.01% | 2345 |
|
|
2015
Q1 | $552K | Hold |
17,600
| – | – | ﹤0.01% | 2123 |
|
|
2014
Q4 | $514K | Buy |
+17,600
| New | +$446K | ﹤0.01% | 2160 |
|
Swiss National Bank's AERI Position: Q4 2022 in Review
Swiss National Bank sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 103,800 shares — an estimated $1.57M sold.
Swiss National Bank first reported a position in AERI in Q4 2014 and held it in 32 quarters. The position peaked at $3.99M in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Swiss National Bank reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Swiss National Bank sold 103,800 Aerie Pharmaceuticals shares in Q4 2022, an estimated $1.57M.
- Swiss National Bank first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 32 quarters.
- Swiss National Bank's Aerie Pharmaceuticals position peaked at $3.99M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Swiss National Bank's 13F filing for Q4 2022, filed 8 Feb 2023.